Astel­las dumps a PhI­II lung can­cer drug; GSK gets one suc­cess, one fail­ure in a pair of piv­otal Crohn’s tri­als

→ Japan’s Astel­las Phar­ma is punt­ing its Phase III drug ASP8273, halt­ing the late-stage SO­LAR tri­al eval­u­at­ing the ef­fi­ca­cy and safe­ty of ASP8273 ver­sus …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.